PharmaEssentia Corporation
6446
Rang in aandelen
#1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aandeelprijs
$36.89
Marktkapitalisatie
$15.25B
Verandering (1 dag)
-1.28%
Verandering (1 jaar)
144.12%
Land
TW
Handel PharmaEssentia Corporation (6446)
Categorie
Healthcare
Winst voor PharmaEssentia Corporation (6446)
Winst in Jun 2026 TTM: $284.95M
Volgens de meest recente financiële verslagen van PharmaEssentia Corporation bedraagt de huidige winst van het bedrijf $284.95M. In 2023 behaalde het bedrijf een winst van $-32.16M, een stijging ten opzichte van de winst van 2022, die $-60.07M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van PharmaEssentia Corporation van 2010 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $284.95M | 212.31% |
| 2024 | $91.24M | -383.66% |
| 2023 | $-32.16M | -46.45% |
| 2022 | $-60.07M | -40.77% |
| 2021 | $-101.42M | 46.26% |
| 2020 | $-69.34M | 146.30% |
| 2019 | $-28.15M | -17.15% |
| 2018 | $-33.98M | 15.54% |
| 2017 | $-29.41M | 12.91% |
| 2016 | $-26.05M | 0.49% |
| 2015 | $-25.92M | -3.64% |
| 2014 | $-26.90M | 35.45% |
| 2013 | $-19.86M | 125.31% |
| 2012 | $-8.81M | 31.09% |
| 2011 | $-6.72M | 17.15% |
| 2010 | $-5.74M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 519.26% |
IN
|
